Your Gateway to Psoriasis Research & Clinical Trials

Most commonly prescribed first-line treatment. Available in multiple potencies from mild (face/folds) to very high (limbs). Reduces inflammation quickly.

Synthetic vitamin D compounds that slow abnormal skin cell growth. Often combined with corticosteroids for enhanced effect and to reduce steroid use.

FDA-approved steroid-free topical approved 2022. Reduces inflammation and regulates skin cell production. ~40% total disease clearance in trials.

A newer steroid-free topical cream. Can be used on all body areas including face, scalp, and skin folds. Suitable as monotherapy or combined with biologics.

The most commonly used form of phototherapy. Delivered 2–3 times weekly in a clinic or home unit. Especially effective for guttate and plaque psoriasis.

Combines a light-sensitizing drug (psoralen) with UVA exposure. More effective than UVB alone but carries higher long-term risks. Used for severe or resistant cases.

A long-established weekly oral or injectable treatment. Effective in ~60% of patients. Also treats psoriatic arthritis and nail psoriasis. Requires regular blood monitoring.

Fast-acting oral immunosuppressant. Used short-term for rapid control of severe flares. Not recommended for continuous long-term use due to kidney and blood pressure risks.

Oral vitamin A derivative that normalizes skin cell turnover. Particularly effective for pustular and erythrodermic psoriasis. Often combined with phototherapy.

First generation of biologics. Block tumor necrosis factor-alpha, a key inflammatory protein. Also treat psoriatic arthritis. Biosimilars now available at lower cost.

Target the IL-17 inflammatory pathway. Among the most effective psoriasis biologics available. Bimekizumab (dual IL-17A/F inhibitor) shows especially strong & rapid results.

Among the newest and most effective biologics. Target IL-23 higher in the inflammatory cascade. Guselkumab is the first IL-23 inhibitor approved for pediatric psoriasis.

Targets both IL-12 and IL-23. Given every 12 weeks after induction. Slightly lower skin clearance than newer biologics but well-established and broadly effective.

FDA-approved biosimilar to Stelara (ustekinumab), approved November 2024 and available from February 2025. Clinically interchangeable with Stelara — equivalent efficacy, safety, and pharmacokinetics proven in the Phase 3 STELLAR-2 trial. Typically available at lower cost than the reference biologic.

Specifically approved for generalized pustular psoriasis (GPP) — a rare and severe form. 54% of patients had no pustules after just 1 week in trials. Monthly dosing.

Oral tablet taken twice daily. No lab monitoring or TB testing required. Modest efficacy compared to biologics but attractive safety profile and convenience.

A newer oral TYK2 inhibitor — a selective, targeted mechanism with no black-box cardiovascular warning unlike JAK inhibitors. 49.5% of patients clear or nearly clear at 16 weeks.

Block Janus kinase signaling pathways. Effective for psoriatic arthritis; under active investigation for plaque psoriasis. Oral convenience but carry FDA black-box warnings.